Panel Backing of OCA was Expected, Leerink Partners Says; Remains Sidelined
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated a Market Perform and $144 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE